Duncan McKechnie, Executive Vice President and Chief Commercial Officer at Vertex Pharmaceuticals (NASDAQ:VRTX), executed stock sales under a company-approved 10b5-1 trading plan, disposing of a total of 4,910 shares on February 25, 2026. Those shares were sold at prices between $486.35 and $489.00, producing proceeds of approximately $2.39 million, according to a Form 4 filed with the Securities and Exchange Commission.
The Form 4 filing documents the February 25 transactions and sits alongside an additional sale by McKechnie on February 24, when he sold 873 shares at $485.11 per share for total proceeds of $423,501. Taken together, the two days of sales total 5,783 shares and roughly $2.81 million in proceeds. After completing these transactions, McKechnie directly holds 17,559 shares of Vertex common stock.
The insider sales occurred as Vertex shares were trading at $480.12, a price level close to the stock's 52-week high of $519.68. The company’s shares have climbed about 24% over the past six months, a rally that leaves some valuation measures extended. InvestingPro analysis cited in the filing indicates Vertex trades at a price-to-earnings ratio of 31.29 and appears overvalued relative to its Fair Value assessment. InvestingPro also assigns Vertex a financial health score of 3.1, described as "GREAT," and notes the availability of 15 additional exclusive tips and metrics for deeper investor review.
Chip-scale corporate fundamentals remain in focus following Vertex's fourth-quarter 2025 results. The company reported revenue of $3.19 billion for the quarter, narrowly topping the forecast of $3.18 billion. On the bottom line, adjusted earnings per share came in at $5.03, a slight miss against the expected $5.08. The mixed earnings print has not halted visible analyst activity around the stock.
Recent analyst moves include Cantor Fitzgerald raising its price target on Vertex to $590 while maintaining an Overweight rating, and Oppenheimer upgrading the company from Perform to Outperform with a $540 price target. Both firms cited the potential of Vertex’s renal pipeline candidates - povetacicept and inaxaplin - as reasons for their positive stance and higher valuations, reflecting continued optimism about the company’s growth trajectory.
The combination of executive selling, a near-term revenue beat, a marginal EPS miss and elevated valuation metrics frames the current investor landscape for Vertex. The Form 4 filing documents the transactions and provides an updated picture of insider ownership following the sales.
Key points
- Duncan McKechnie sold 4,910 shares on February 25, 2026 at $486.35 to $489.00 per share under a 10b5-1 plan, producing approximately $2.39 million.
- McKechnie additionally sold 873 shares on February 24 at $485.11 for $423,501; he now directly owns 17,559 shares.
- Vertex reported Q4 2025 revenue of $3.19 billion, slightly above the $3.18 billion forecast, while EPS of $5.03 missed the $5.08 expectation; analysts have raised price targets citing renal pipeline potential.
Summary
The chief commercial officer of Vertex Pharmaceuticals sold multiple blocks of stock under a pre-established trading plan across February 24-25, 2026, generating roughly $2.81 million in proceeds. The sales were reported in a Form 4 filing. The activity comes as Vertex shares trade near their 52-week high and after the company posted quarterly revenue marginally above estimates while missing EPS expectations by a narrow margin. Analysts from Cantor Fitzgerald and Oppenheimer have recently increased price targets and ratings, citing the company’s renal candidates as a catalyst for future growth.
Risks and uncertainties
- Valuation risk - InvestingPro flags Vertex as trading above its Fair Value with a P/E of 31.29, indicating potential valuation concerns for equity investors in the biotech sector.
- Earnings uncertainty - Vertex’s EPS for Q4 2025 came in slightly below consensus at $5.03 versus an expected $5.08, introducing near-term earnings variability.
- Insider holdings change - The recent sales reduced McKechnie’s direct ownership to 17,559 shares, a fact investors may consider when assessing insider alignment.